{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(23)"],"submitter":["Khanna A"],"pubmed_abstract":["Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would be an attractive therapeutic approach.Our analysis of over three hundred clinical samples and patient-derived prostate epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to the intronic region of CIP2A and its functionality in"],"journal":["Oncotarget"],"pagination":["19661-70"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4637312"],"repository":["biostudies-literature"],"pubmed_title":["CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations."],"pmcid":["PMC4637312"],"pubmed_authors":["Kivinummi KK","Helenius MA","Maitland NJ","Tolonen TT","Manni V","Latonen L","Saramaki OR","Visakorpi T","Khanna A","Urbanucci A","Pimanda JE","Rane JK","Westermarck J"],"additional_accession":[]},"is_claimable":false,"name":"CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.","description":"Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would be an attractive therapeutic approach.Our analysis of over three hundred clinical samples and patient-derived prostate epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to the intronic region of CIP2A and its functionality in","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Aug","modification":"2026-05-09T15:49:56.041Z","creation":"2019-03-27T02:01:33Z"},"accession":"S-EPMC4637312","cross_references":{"pubmed":["25965834"],"doi":["10.18632/oncotarget.3875"]}}